Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

11 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Clinical and Immunologic Characteristics of Colorectal Cancer Tumors Expressing LY6G6D.
Sanvicente García A, Pedregal M, Paniagua-Herranz L, Díaz-Tejeiro C, Nieto-Jiménez C, Pérez Segura P, Munkácsy G, Győrffy B, Calvo E, Moreno V, Ocaña A. Sanvicente García A, et al. Among authors: pedregal m. Int J Mol Sci. 2024 May 14;25(10):5345. doi: 10.3390/ijms25105345. Int J Mol Sci. 2024. PMID: 38791382 Free PMC article.
Genomic and Immunologic Correlates in Prostate Cancer with High Expression of KLK2.
Paniagua-Herranz L, Moreno I, Nieto-Jiménez C, Garcia-Lorenzo E, Díaz-Tejeiro C, Sanvicente A, Doger B, Pedregal M, Ramón J, Bartolomé J, Manzano A, Gyorffy B, Gutierrez-Uzquiza Á, Pérez Segura P, Calvo E, Moreno V, Ocana A. Paniagua-Herranz L, et al. Among authors: pedregal m. Int J Mol Sci. 2024 Feb 13;25(4):2222. doi: 10.3390/ijms25042222. Int J Mol Sci. 2024. PMID: 38396898 Free PMC article.
A Risk-benefit Analysis of Prophylactic Anticoagulation for Patients with Metastatic Germ Cell Tumours Undergoing First-line Chemotherapy.
Fankhauser CD, Tran B, Pedregal M, Ruiz-Morales JM, Gonzalez-Billalabeitia E, Patrikidou A, Amir E, Seidel C, Bokemeyer C, Hermanns T, Rumyantsev A, Tryakin A, Brito M, Fléchon A, Kwan EM, Cheng T, Castellano D, Del Muro XG, Hamid AA, Ottaviano M, Palmieri G, Kitson R, Reid A, Heng DYC, Bedard PL, Sweeney CJ, Connors JM. Fankhauser CD, et al. Among authors: pedregal m. Eur Urol Focus. 2021 Sep;7(5):1130-1136. doi: 10.1016/j.euf.2020.09.017. Epub 2020 Oct 6. Eur Urol Focus. 2021. PMID: 33032968 Free article.
A Call for Standardized Reporting of Adverse Events.
Fankhauser CD, Wettstein MS, Pedregal M, Clarke NW, Sweeney CJ. Fankhauser CD, et al. Among authors: pedregal m. Eur Urol. 2020 Sep;78(3):481-482. doi: 10.1016/j.eururo.2020.06.052. Epub 2020 Jul 4. Eur Urol. 2020. PMID: 32636097 Free article. No abstract available.
Neutrophil-lymphocyte ratio kinetics in patients with advanced solid tumours on phase I trials of PD-1/PD-L1 inhibitors.
Ameratunga M, Chénard-Poirier M, Moreno Candilejo I, Pedregal M, Lui A, Dolling D, Aversa C, Ingles Garces A, Ang JE, Banerji U, Kaye S, Gan H, Doger B, Moreno V, de Bono J, Lopez J. Ameratunga M, et al. Among authors: pedregal m. Eur J Cancer. 2018 Jan;89:56-63. doi: 10.1016/j.ejca.2017.11.012. Epub 2017 Dec 8. Eur J Cancer. 2018. PMID: 29227818 Clinical Trial.
CIP2A confirms its prognostic value in triple-negative breast cancer.
Cristóbal I, Zazo S, Torrejón B, Pedregal M, Madoz-Gúrpide J, Lluch A, Eroles P, Rovira A, Albanell J, García-Foncillas J, Rojo F. Cristóbal I, et al. Among authors: pedregal m. Oncogene. 2017 Jun 8;36(23):3357-3358. doi: 10.1038/onc.2016.474. Epub 2017 Jan 9. Oncogene. 2017. PMID: 28068327 No abstract available.
Targeting PP2A to overcome enzalutamide resistance in AR+ breast tumors.
Cristóbal I, Torrejón B, Pedregal M, Rojo F, García-Foncillas J. Cristóbal I, et al. Among authors: pedregal m. Endocr Relat Cancer. 2017 Jan;24(1):L5-L6. doi: 10.1530/ERC-16-0444. Epub 2016 Oct 20. Endocr Relat Cancer. 2017. PMID: 27765801 No abstract available.
11 results